CSIMarket


Integrated Biopharma Inc  (INBP)
Other Ticker:  
 
 

INBP's Income from Cont. Operations Growth by Quarter and Year

Integrated Biopharma Inc's Income from Cont. Operations results by quarter and year




INBP Income from Cont. Operations (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter June - 4.51 1.90 0.36
III Quarter March - 1.24 0.94 0.92
II Quarter December - 1.22 0.96 0.25
I Quarter September 0.52 1.04 0.31 0.16
FY   0.52 8.01 4.11 1.69



INBP Income from Cont. Operations first quarter 2021 Y/Y Growth Comment
Integrated Biopharma Inc reported drop in Income from Cont. Operations in the first quarter by -50.38% to $ 0.52 millions, from the same quarter in 2020.
The fall in the first quarter Integrated Biopharma Inc's Income from Cont. Operations compares unfavorably to the Company's average Income from Cont. Operations doubling of 193.53%.

Looking into first quarter results within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Income from Cont. Operations growth. While Integrated Biopharma Inc' s Income from Cont. Operations meltdown of -50.38% ranks overall at the positon no. 1812 in the first quarter.




INBP Income from Cont. Operations ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter June - 137.37 % 427.78 % -63.27 %
III Quarter March - 31.91 % 2.17 % 109.09 %
II Quarter December - 27.08 % 284 % -
I Quarter September -50.38 % 235.48 % 93.75 % -
FY   - 94.89 % 143.2 % 89.89 %

Financial Statements
Integrated Biopharma Inc's first quarter 2021 Income from Cont. Operations $ 0.52 millions INBP's Income Statement
Integrated Biopharma Inc's first quarter 2020 Income from Cont. Operations $ 1.04 millions Quarterly INBP's Income Statement
New: More INBP's historic Income from Cont. Operations Growth >>


INBP Income from Cont. Operations (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter June - 263.71 % 102.13 % -60.87 %
III Quarter March - 1.64 % -2.08 % 268 %
II Quarter December - 17.31 % 209.68 % 56.25 %
I Quarter September -88.56 % -45.26 % -13.89 % -83.67 %
FY (Year on Year)   - 94.89 % 143.2 % 89.89 %




Income from Cont. Operations first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #133
Overall #1812

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
1309.43 % 193.53 % -63.23 %
(Jun 30 2016)   (Jun 30 2019)
Income from Cont. Operations first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #133
Overall #1812
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
1309.43 % 193.53 % -63.23 %
(Jun 30 2016)   (Jun 30 2019)

Income from Cont. Operations by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Integrated Biopharma Inc's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
2163.64 % 194.91 % -88.55 %
(Jun 30 2016)  


INBP's I. Quarter Q/Q Income from Cont. Operations Comment
In the I. Quarter 2021 Integrated Biopharma Inc reported fall in Income from Cont. Operations from the forth quarter by -88.56% to $ 0.52 millions, from $ 4.51 millions declared a quarter before.

If you evaluate recent shortcoming at the I. Quarter, you suppose to presume, that usually I. Quarter performance appear to be softer then in the quarter before, Edoardo Giordano, an industry insider added.

Within Biotechnology & Pharmaceuticals industry 17 other companies have achieved higher Income from Cont. Operations quarter on quarter growth. While Integrated Biopharma Inc's Income from Cont. Operations growth quarter on quarter, overall rank is 1885.


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #18
Healthcare Sector #138
Overall #1885
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #18
Healthcare Sector #138
Overall #1885
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
2163.64 % 194.91 % -88.55 %
(Jun 30 2016)  


INBP's I. Quarter Q/Q Income from Cont. Operations Comment
In the I. Quarter 2021 Integrated Biopharma Inc reported fall in Income from Cont. Operations from the previous quarter by -88.56% to $ 0.52 millions, from $ 4.51 millions declared in the previous quarter.

When you analyse current downturn in the I. Quarter 2021, you suppose to take into consideration, that usually I. Quarter performance emerge softer then in the quarter before

Within Biotechnology & Pharmaceuticals industry 17 other companies have achieved higher Income from Cont. Operations quarter on quarter growth. While Integrated Biopharma Inc's Income from Cont. Operations growth quarter on quarter, overall rank is 1885.


Integrated Biopharma Inc's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
Cumulative Income from Cont. Operations 12 Months Ending $ 7.49 $ 8.01 $ 5.41 $ 5.10 $ 4.84
Y / Y Income from Cont. Operations Growth (TTM) 54.81 % 95.06 % 110.63 % 99.77 % 162.74 %
Year on Year Income from Cont. Operations Growth Overall Ranking # 684 # 550 # 241 # 252 # 133
Seqeuential Income from Cont. Operations Change (TTM) -6.55 % 48.2 % 5.98 % 5.48 % 17.75 %
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # 1582 # 393 # 1112 # 1029 # 523




Cumulative Income from Cont. Operations growth Comment
With the quarterly Income from Cont. Operations reported in the Sep 30 2021 period, Integrated Biopharma Inc's cumulative twelve months Income from Cont. Operations were $ 7 millions, company would post below average annual Income from Cont. Operations growth of 17.75% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Integrated Biopharma Inc's Income from Cont. Operations growth from the 4.51% growth in Jun 30 2021.

In the Healthcare sector 40 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Income from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 550 to 684.

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
262.88 %
18.96 %
-84.7 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 14
Healthcare Sector # 41
Overall # 684

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
981.6 %
107.4 %
-79.44 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 14
Sector # 114
S&P 500 # 1582
Cumulative Income from Cont. Operations growth Comment
With the quarterly Income from Cont. Operations reported in the Sep 30 2021 period, Integrated Biopharma Inc's cumulative twelve months Income from Cont. Operations were $ 7 millions, company would post below average annual Income from Cont. Operations growth of -79.44% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Integrated Biopharma Inc's Income from Cont. Operations growth from the 4.51% growth in Jun 30 2021.

In the Healthcare sector 40 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Income from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 550 to 684.

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
262.88 %
18.96 %
-84.7 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 14
Healthcare Sector # 41
Overall # 684

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
981.6 %
107.4 %
-79.44 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 14
Sector # 114
S&P 500 # 1582




Other Income from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
INBP's Income from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for INBP's Competitors
Income from Cont. Operations Growth for Integrated Biopharma Inc's Suppliers
Income from Cont. Operations Growth for INBP's Customers

You may also want to know
INBP's Annual Growth Rates INBP's Profitability Ratios INBP's Asset Turnover Ratio INBP's Dividend Growth
INBP's Roe INBP's Valuation Ratios INBP's Financial Strength Ratios INBP's Dividend Payout Ratio
INBP's Roa INBP's Inventory Turnover Ratio INBP's Growth Rates INBP's Dividend Comparisons



Companies with similar Income from Cont. Operations fall for the quarter ending Sep 30 2021 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2021
Dexcom Inc -1.80%$ -1.801 millions
Owens and Minor Inc -4.24%$ -4.236 millions
United Therapeutics Corporation-4.96%$ -4.965 millions
Amgen Inc -6.78%$ -6.779 millions
Quidel Corporation-7.11%$ -7.111 millions
Eli Lilly And Company-8.13%$ -8.135 millions
Abiomed Inc -8.45%$ -8.455 millions
Universal Health Services Inc -10.13%$ -10.126 millions
U S Physical Therapy Inc-10.40%$ -10.404 millions
Quest Diagnostics Inc-10.83%$ -10.829 millions
Lemaitre Vascular Inc-13.43%$ -13.430 millions
Vyne Therapeutics Inc -13.87%$ -13.875 millions
Semler Scientific inc -14.71%$ -14.714 millions
Laboratory Corporation Of America Holdings-16.47%$ -16.470 millions
Bristol Myers Squibb Co-17.36%$ -17.359 millions
Electromed Inc -17.98%$ -17.984 millions
Nature s Sunshine Products inc -23.87%$ -23.867 millions
Immune Therapeutics Inc -23.97%$ -23.971 millions
Petmed Express Inc-24.52%$ -24.524 millions
Co diagnostics Inc -27.05%$ -27.051 millions
Elite Pharmaceuticals Inc -27.59%$ -27.587 millions
Collegium Pharmaceutical inc -28.71%$ -28.708 millions
Biodelivery Sciences International Inc -28.92%$ -28.925 millions
Stryker Corp-29.47%$ -29.469 millions
Fitlife Brands Inc -31.61%$ -31.611 millions
Hologic Inc-33.29%$ -33.293 millions
Msa Safety Inc-33.33%$ -33.332 millions
Steris Plc-34.32%$ -34.321 millions
Viemed Healthcare Inc -36.20%$ -36.198 millions
Amedisys Inc-37.52%$ -37.516 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

MNTM's Profile

Stock Price

MNTM's Financials

Business Description

Fundamentals

Charts & Quotes

MNTM's News

Suppliers

MNTM's Competitors

Customers & Markets

Economic Indicators

MNTM's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071